Chlibek R, Smetana J, Sosovickova R, Fabianova K, Zavadilova J, Dite P, Gal P, Naplava P, Lzicarova D
Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic.
Public Health. 2017 Sep;150:77-83. doi: 10.1016/j.puhe.2017.05.012. Epub 2017 Jun 21.
Despite widespread vaccination programmes, pertussis remains a significant health burden in many countries. Low awareness of the disease, the high rate of asymptomatic cases in adults and difficulties with diagnosis could explain the under-reporting of pertussis. The lack of data on actual incidence constitutes an obstacle for public health authorities for the implementation of a vaccination strategy against pertussis in adults. The aim of this study was to evaluate the seroprevalence of antibodies against Bordetella pertussis infection in adults and to estimate the actual incidence of the disease compared with the reported incidence.
Prospective, multicentre seroprevalence study.
The study was conducted in 2000 adult subjects aged ≥18 years who had not received pertussis vaccination within the last 5 years. All enrolled subjects provided a blood sample for serum testing of IgG antibodies against pertussis toxin, performed by enzyme-linked immunosorbent assay, to indicate if they had an acute infection or if they had been infected with pertussis within the last 12 months or earlier. Results were validated in accordance with the guidelines of the European Sero-epidemiology Network 2 and were expressed in ESEN units/ml.
A positive concentration of anti-pertussis toxin antibodies, indicating previous pertussis infection, was demonstrated in 39.9% (n = 799) of all study subjects, and 0.40% (n = 8) of subjects had a concentration suggestive of a recent infection (within the last 12 months). The highest antibody seroprevalence was observed in subjects aged 18-29 years (1.46%). No cases of acute infection were detected.
During the study period, the reported incidence of pertussis in the adult population was 0.84/100,000 inhabitants. Based on the seroprevalence results from this study, it is estimated that the actual incidence of pertussis could be as much as 699/100,000 inhabitants. The actual incidence of pertussis in adults in the Czech Republic could therefore be at least 200-fold higher than the reported incidence. These findings support the need for pertussis vaccination in the adult population.
尽管有广泛的疫苗接种计划,但百日咳在许多国家仍然是一个重大的健康负担。对该疾病的认识不足、成人无症状病例的高比例以及诊断困难可能解释了百日咳报告不足的情况。缺乏实际发病率的数据构成了公共卫生当局在成人中实施百日咳疫苗接种策略的障碍。本研究的目的是评估成人中抗百日咳博德特氏菌感染抗体的血清阳性率,并与报告发病率相比估计该疾病的实际发病率。
前瞻性多中心血清阳性率研究。
该研究针对2000名年龄≥18岁且在过去5年内未接种过百日咳疫苗的成年人进行。所有入选受试者均提供血样,通过酶联免疫吸附测定法检测血清中抗百日咳毒素IgG抗体,以表明他们是否有急性感染,或者在过去12个月内或更早是否感染过百日咳。结果按照欧洲血清流行病学网络2的指南进行验证,并以ESEN单位/毫升表示。
在所有研究受试者中,39.9%(n = 799)的人抗百日咳毒素抗体浓度呈阳性,表明既往感染过百日咳,0.40%(n = 8)的受试者浓度提示近期感染(在过去12个月内)。18 - 29岁的受试者中观察到最高的抗体血清阳性率(1.46%)。未检测到急性感染病例。
在研究期间,成人百日咳报告发病率为0.84/10万居民。根据本研究的血清阳性率结果,估计百日咳的实际发病率可能高达至699/10万居民。因此,捷克共和国成人百日咳的实际发病率可能比报告发病率至少高200倍。这些发现支持了在成人中进行百日咳疫苗接种的必要性。